Tracing Synaptic Loss in Alzheimer's Brain with SV2A PET-tracer UCB-J

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2024 Feb 16

PMID 38363009

Authors

Amit Kumar

Miriam Scarpa

Agneta Nordberg

Affiliations

Soon will be listed here.

Abstract

Introduction: Synaptic loss is an early prominent feature of Alzheimer's disease (AD). The recently developed novel synaptic vesicle 2A protein (SV2A) PET-tracer UCB-J has shown great promise in tracking synaptic loss in AD. However, there have been discrepancies between the findings and a lack of mechanistic insight.

Methods: Here we report the first extensive pre-clinical validation studies for UCB-J in control (CN; n = 11) and AD (n = 11) brains using a multidimensional approach of post-mortem brain imaging techniques, radioligand binding, and biochemical studies.

Results And Discussion: We demonstrate that UCB-J could target SV2A protein with high specificity and depict synaptic loss at synaptosome levels in AD brain regions compared to CNs. UCB-J showed highest synaptic loss in AD hippocampus followed in descending order by frontal cortex, temporal cortex, parietal cortex, and cerebellum. H-UCB-J large brain-section autoradiography and cellular/subcellular fractions binding studies indicated potential off-target interaction with phosphorylated tau (p-tau) species in AD brains, which could have subsequent clinical implications for imaging studies.

Highlights: Synaptic positron emission tomography (PET)-tracer UCB-J could target synaptic vesicle 2A protein (SV2A) with high specificity in Alzheimer's disease (AD) and control brains. Synaptic PET-tracer UCB-J could depict synaptic loss at synaptosome levels in AD brain regions compared to control. Potential off-target interaction of UCB-J with phosphorylated tau (p-tau) species at cellular/subcellular levels could have subsequent clinical implications for imaging studies, warranting further investigations.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.

Synapse vulnerability and resilience underlying Alzheimer's disease.

Taddei R, E Duff K EBioMedicine. 2025; 112:105557.

PMID: 39891995 PMC: 11833146. DOI: 10.1016/j.ebiom.2025.105557.

Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment.

Vanderlinden G, Koole M, Michiels L, Lemmens R, Vandenbulcke M, Van Laere K Alzheimers Dement. 2024; 21(2):e14412.

PMID: 39732507 PMC: 11848342. DOI: 10.1002/alz.14412.

Post mortem validation and mechanistic study of UCB-J in progressive supranuclear palsy patients' brains.

Scarpa M, Vallera E, Auselle-Bosch S, Rocha F, Mercan B, Roy A Alzheimers Dement. 2024; 21(2):e14409.

PMID: 39670533 PMC: 11848344. DOI: 10.1002/alz.14409.

SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes.

Snellman A, Tuisku J, Koivumaki M, Wahlroos S, Aarnio R, Rajander J Alzheimers Dement. 2024; 20(12):8802-8813.

PMID: 39475191 PMC: 11667521. DOI: 10.1002/alz.14327.

References

Zimmer E, Parent M, Souza D, Leuzy A, Lecrux C, Kim H . [F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 2017; 20(3):393-395. PMC: 5378483. DOI: 10.1038/nn.4492. View

Holland N, Jones P, Savulich G, Naessens M, Malpetti M, Whiteside D . Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo [ C]UCB-J Positron Emission Tomography Study. Mov Disord. 2023; 38(7):1316-1326. PMC: 10947001. DOI: 10.1002/mds.29421. View

Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E . Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry. 2022; 27(10):4244-4251. DOI: 10.1038/s41380-022-01672-x. View

Bajjalieh S, Frantz G, Weimann J, McConnell S, Scheller R . Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994; 14(9):5223-35. PMC: 6577109. View

Chng T, Martin K . Synapse-to-nucleus signaling. Curr Opin Neurobiol. 2011; 21(2):345-52. PMC: 3092794. DOI: 10.1016/j.conb.2011.01.011. View

Finnema S, Nabulsi N, Eid T, Detyniecki K, Lin S, Chen M . Imaging synaptic density in the living human brain. Sci Transl Med. 2016; 8(348):348ra96. DOI: 10.1126/scitranslmed.aaf6667. View

Heurling K, Ashton N, Leuzy A, Zimmer E, Blennow K, Zetterberg H . Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Mol Cell Neurosci. 2019; 97:34-42. DOI: 10.1016/j.mcn.2019.02.001. View

Lepeta K, Lourenco M, Schweitzer B, Martino Adami P, Banerjee P, Catuara-Solarz S . Synaptopathies: synaptic dysfunction in neurological disorders - A review from students to students. J Neurochem. 2016; 138(6):785-805. PMC: 5095804. DOI: 10.1111/jnc.13713. View

Scheff S, Price D . Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis. 2006; 9(3 Suppl):101-15. DOI: 10.3233/jad-2006-9s312. View

10.

Mecca A, Chen M, ODell R, Naganawa M, Toyonaga T, Godek T . In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimers Dement. 2020; 16(7):974-982. PMC: 7383876. DOI: 10.1002/alz.12097. View

11.

Tzioras M, McGeachan R, Durrant C, Spires-Jones T . Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2022; 19(1):19-38. DOI: 10.1038/s41582-022-00749-z. View

12.

Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S . Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. Mol Imaging Biol. 2019; 22(4):832-841. DOI: 10.1007/s11307-019-01428-0. View

13.

Chen M, Mecca A, Naganawa M, Finnema S, Toyonaga T, Lin S . Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018; 75(10):1215-1224. PMC: 6233853. DOI: 10.1001/jamaneurol.2018.1836. View

14.

McInnes J, Wierda K, Snellinx A, Bounti L, Wang Y, Stancu I . Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau. Neuron. 2018; 97(4):823-835.e8. DOI: 10.1016/j.neuron.2018.01.022. View

15.

Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky S . The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimers Res Ther. 2020; 12(1):21. PMC: 7053087. DOI: 10.1186/s13195-020-00588-4. View

16.

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

17.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

18.

Kumar A, Koistinen N, Malarte M, Nennesmo I, Ingelsson M, Ghetti B . Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. Mol Psychiatry. 2021; 26(10):5833-5847. PMC: 8758481. DOI: 10.1038/s41380-021-01101-5. View

19.

Sahara N, Murayama M, Higuchi M, Suhara T, Takashima A . Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau. Front Neurol. 2014; 5:26. PMC: 3949102. DOI: 10.3389/fneur.2014.00026. View

20.

Fontana I, Kumar A, Okamura N, Nordberg A . Multitracer Approach to Understanding the Complexity of Reactive Astrogliosis in Alzheimer's Brains. ACS Chem Neurosci. 2023; 15(2):328-336. PMC: 10797624. DOI: 10.1021/acschemneuro.3c00646. View